First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: New England Journal of Medicine
Authors: Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine A. Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro, Li Zheng, John V. Heymach
Institutions: First Affiliated Hospital of Guangzhou Medical University, Shanghai East Hospital, Assistance Publique Hôpitaux de Marseille, Hôpital Nord, University Health Network, Princess Margaret Cancer Centre, Peter MacCallum Cancer Centre, Shandong Tumor Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Ohio State University Hospital, The Ohio State University, Gazi University, Jinan Central Hospital, Shandong First Medical University, Columbia University Irving Medical Center, Centre Hospitalier Universitaire de Nantes, Zhejiang Cancer Hospital, Clinica Universidad de Navarra, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Peking Union Medical College Hospital, Azienda Ospedaliero-Universitaria di Modena, University of Colorado Hospital, University of Colorado Cancer Center, University of Colorado Anschutz, Institut de Cancérologie de l'Ouest, Fudan University, Zhongshan Hospital, Peking University Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, First Hospital of China Medical University, Third Affiliated Hospital of Harbin Medical University, Azienda Ospedaliero-Universitaria Careggi, Centre Hospitalier Universitaire de Grenoble, Hôpital Albert Michallon, Hôpital Foch, Instituto do Câncer do Estado de São Paulo, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162799555